Associated Papers
Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer.
Vendrell JA et al.
International Journal of Molecular Sciences, 2023
37762485 (PubMed )
Supplement: ijms-24-14181-s001.zip › Table_S2.xlsx › Supplementary_Table_2
Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma.
Pitiyarachchi O et al.
Translational Oncology, 2023
36805919 (PubMed )
Supplement: mmc1.docx
Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency.
Bajrami I et al.
Communications Biology, 2021
34750509 (PubMed )
Supplement: 42003_2021_2770_MOESM9_ESM.xlsx › Fig_S13
Copy number signatures and mutational processes in ovarian carcinoma.
Macintyre G et al.
Nature Genetics, 2018
30104763 (PubMed )
Supplement: NIHMS78219-supplement-3.xlsx › mutated_cases
Select a paper to view details